Subject: ONCX CEO Outlines Productive 2017 and 2018 Outlook

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
ONCX CEO Outlines Productive 2017 and 2018 Outlook
Hot Stock to WatchHot Stock to Watch

Company: Oncolix, Inc. (Pink Sheets: ONCX)


Price: 0.0498

Change (%): + 0.00 (0.00)

Volume: 526
ONCX Chart

Michael T. Redman, Chairman of the Board and CEO of Oncolix, Inc., Provides Progress Report and Outlook for Investors in New Audio Interview at

AUSTIN, Texas, Dec. 13, 2017 (GLOBE NEWSWIRE) -, Inc. (SCV) and Oncolix, Inc. (“The Company”) (OTC:ONCX), a biotechnology company focused on gynecological cancers, today announced that a new audio interview with the Company is now available. The interview can be heard at

Michael T. Redman, called in to to go discuss the recent news regarding the change in the Company’s stock symbol to ONCX, the appointment of John W. Holaday, Ph.D., to the Company’s Board of Directors which fulfills an OTC-QB listing requirement, an update on the clinical trials for Prolanta, the next steps for the ONCX on its path to a higher exchange, what investors can expect from the Company in 2018, and more.

In the interview Mr. Redman stated, “The most important thing, in the very short term is completing the up-listing from Pink Sheets to the OTC QB. I want to see this done as soon as possible. The next most important goal is to show that we are continuing to treat the patients in the clinical trials. We’re making very good headway in that regard.”

A more information about the Company from can be found here:

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks